

Invitation
Swiss Hepatitis Symposium 2025

«Viral Hepatitis:

**Micro-elimination among People
in Opioid Agonist Therapy (OAT)
and People Using Substances**

Monday 8 December 2025, 1.30 to 6 pm
Welle7, Bern

Chaired by Catherine Boss, reporter Research Desk Tamedia

Welcome

We are delighted to welcome you to the Swiss Hepatitis Symposium, an event dedicated to advancing dialogue, collaboration, and solutions in the field of viral hepatitis. This year's program brings together leading experts, healthcare professionals, researchers, and patient voices to explore barriers and gaps in hepatitis care for individuals who use substances.

Through a series of presentations, different perspectives will be highlighted, followed by a personal interview with a patient to bring lived experience into focus. The afternoon will culminate in an interactive World Café session, fostering exchange on innovative approaches, challenges, and opportunities in Hepatitis care.

To ensure that discussions are meaningful and lead to concrete outcomes, we kindly request that the participants join the symposium on-site.

Together, we aim to build a more connected community committed to eliminating viral Hepatitis and improving care for all affected populations.

We thank you for joining us and look forward to your contributions throughout this exchange.

Philip Bruggmann
Swiss Hepatitis

Thomas Steffen
The Swiss Society for Public Health

Programme

Start of the symposium (13:30)

13:30	Welcome to the symposium	Philip Bruggmann , Swiss Hepatitis Bettina Maeschli , The Swiss Society for Public Health
13:40	Interventions to improve Hepatitis C Care towards the elimination	Evan Cunningham , Kirby Institute, UNSW, Australia
14:10	Q&A Session	
14:15	Swiss National Data and Perspective	
	1. Characteristics and comorbidities of patients on opioid agonist therapy in Switzerland: a descriptive analysis of the nationwide SAMMSU* cohort	Thomas Grischott , Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich
	2. Hepatitis B and D testing and prevalence in the nationwide SAMMSU* cohort	Claudia Bernardini , Arud Zurich
	3. Hepatitis C cascade of care among patients in the decentralised opioid agonist therapy programme: a cross-sectional study	Kerstin Wissel , Checkpoint Zurich
	4. Assessment of the quality of Hepatitis C Care in the decentralized OAT setting in Switzerland	Lorena Reinschmidt , St. Claraspital, Basel

*Swiss Association for the medical management in substance users (SAMMSU)

Coffee Break (15:15)

15:45	Peer Person Perspective (Interview)	Interviewer: Erika Castro , Primary care physician, Lausanne
15:55	World Café	
	Table 1: Patient engagement and education as primary care physician (without OAT)	Oliver Senn , Institute of Primary Care, University Hospital Zurich, University of Zurich, Zurich
	Table 2: Hepatitis Care in an OAT Program without primary health care	Adrian Kormann , HeGeBe ZOPA Zug
	Table 3: Role of Nursing in Hepatitis Care	tbd
	Table 4: Barriers of Hepatitis Care in a practitioner's office	Erika Castro , Primary Health Care physician, SAMMSU president
17:40	Closing Remarks & Outlook	Catherine Boss

End of symposium and apéro riche (18:00)

All talks are in English. Translation will be provided by the AI tool "wordly". Contributions from the audience in German or French are welcome and will be translated ad hoc.

Login and registration


You can register [here](#) or send an e-mail to info@hepatitis-schweiz.ch. Please register by 30 November 2025.

The event is free of charge.

Venue

Welle7 Workspace, Eventraum
Schanzenstrasse 5, 3008 Bern, Switzerland


Directions



Contact

info@hepatitis-schweiz.ch, +41 58 360 51 66, www.hepatitis-schweiz.ch

With the kind support of:



Sponsored by:



Credits by:

